Courtois Philippe, Jijakli Hassan, Ladriere Laurence, Oguzhan Berrin, Sener Abdullah, Malaisse Willy J
Laboratory of Experimental Medicine, Brussels Free University, B-1070 Brussels, Belgium.
Int J Mol Med. 2003 Jan;11(1):105-9.
Control and streptozotocin-induced diabetic rats, as well as GK rats, received a single oral administration of either nateglinide (50 microg/g body wt.) or glibenclamide (1.0 microg/g body wt.). The plasma D-glucose and insulin concentrations, as well as the content of plasma, liver and pancreas in either nateglinide or glibenclamide were measured 60 min or 24 hours after the administration of these antidiabetic agents. At the 60th min, the plasma, hepatic and pancreatic content of nateglinide largely exceeded that of glibenclamide. At the 24th hour, however, the plasma concentration, as well as liver and pancreas content, of nateglinide became negligible, whilst that of glibenclamide exceeded the values recorded at the 60th min. A comparable pattern characterized the insulinotropic action and hypoglycemic effect of these two antidiabetic agents. This study thus emphasizes the vastly different pharmacodynamics of nateglinide and glibenclamide in both control and diabetic rats.
对照大鼠、链脲佐菌素诱导的糖尿病大鼠以及 GK 大鼠,均单次口服给予那格列奈(50 微克/克体重)或格列本脲(1.0 微克/克体重)。在给予这些抗糖尿病药物 60 分钟或 24 小时后,测量血浆 D - 葡萄糖和胰岛素浓度,以及那格列奈或格列本脲在血浆、肝脏和胰腺中的含量。在第 60 分钟时,那格列奈在血浆、肝脏和胰腺中的含量大大超过格列本脲。然而,在第 24 小时时,那格列奈的血浆浓度以及在肝脏和胰腺中的含量变得可忽略不计,而格列本脲的浓度超过了第 60 分钟时记录的值。这两种抗糖尿病药物的促胰岛素分泌作用和降血糖作用呈现出类似的模式。因此,本研究强调了那格列奈和格列本脲在对照大鼠和糖尿病大鼠中截然不同的药效学特性。